Glitazones Take New Hit for Bladder Cancer Risk

May 24, 2012

MedPage Today

As reported in MedPage Today, British patients followed after starting on glitazone drugs for type 2 diabetes were significantly more likely to develop bladder cancer than those taking sulfonylurea agents, according to a new Penn study that will be presented at this year's meeting of the American Society of Clinical Oncology. The increased risk of bladder cancer associated with glitazones -- which reached a relative increase of 72 percent in patients who started on the agents more than 5 years earlier -- "appears to be a class effect," said Ronac Mamtani, MD, the study's leader and a fellow in the division of Hematology/Oncology. However, the analysis of some 60,000 patients indicated that pioglitazone (Actos) posed no more risk than rosiglitazone (Avandia), according to the study, which will be presented at ASCO's annual meeting early next month... Read More

Related Information